Gene-guided chemotherapy for early-stage pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether choosing chemotherapy based on a SMAD4 gene change in your tumor works better than the usual approach for pancreatic cancer that can be surgically removed. If you have the gene change, you may get a different chemotherapy combination to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that is either removable by surgery now or might become removable after shrinking.
- You must have had a genetic test (called NGS) on your tumor to check for a SMAD4 gene change. You can join whether the gene is normal or changed.
- You must not have had chemotherapy or radiation for this cancer before starting.
- You must be 18 or older and generally well enough to receive intensive chemotherapy.
- You cannot have certain other gene changes (like Lynch syndrome) or unstable health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before surgery to shrink the tumor in people with a specific type of pancreatic cancer. The goal is to make surgery more effective and improve outcomes.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
This study uses MRI scans to see how well chemotherapy and radiation work in people with borderline resectable pancreatic cancer – a type where surgery might be possible but is risky. The goal is to find the best way to measure tumor response so doctors can make better treatment decisions.
This trial tests a combination of three chemotherapy drugs given before surgery for pancreatic cancer that is removable or borderline removable. The goal is to shrink the tumor to make surgery more successful.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.